These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16969853)

  • 1. Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft.
    Jung JH; Min PK; Kim JY; Park S; Choi EY; Ko YG; Choi D; Jang Y; Shim WH; Cho SY
    Catheter Cardiovasc Interv; 2006 Oct; 68(4):567-73. PubMed ID: 16969853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
    Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
    J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results and predictors of angiographic restenosis and long-term adverse cardiac events after drug-eluting stent implantation for aorto-ostial coronary artery disease.
    Park DW; Hong MK; Suh IW; Hwang ES; Lee SW; Jeong YH; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2007 Mar; 99(6):760-5. PubMed ID: 17350360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
    Moussa I; Leon MB; Baim DS; O'Neill WW; Popma JJ; Buchbinder M; Midwall J; Simonton CA; Keim E; Wang P; Kuntz RE; Moses JW
    Circulation; 2004 May; 109(19):2273-8. PubMed ID: 15123524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
    Waksman R; Ajani AE; Pichard AD; Torguson R; Pinnow E; Canos D; Satler LF; Kent KM; Kuchulakanti P; Pappas C; Gambone L; Weissman N; Abbott MC; Lindsay J;
    J Am Coll Cardiol; 2004 Oct; 44(7):1386-92. PubMed ID: 15464317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of "Cypher" sirolimus-eluting stents in coronary heart disease patients with different types of coronary arterial lesions].
    Belenkov IuN; Matchin IuG; Liakishev AA; Savchenko AP
    Vestn Rentgenol Radiol; 2006; (3):4-12. PubMed ID: 17407958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients.
    Arruda JA; Costa MA; Brito FS; Tedesco H; Barbosa AH; Ribeiro EP; Pestana JO; Lima VC
    Am J Cardiol; 2003 Jun; 91(11):1363-5. PubMed ID: 12767437
    [No Abstract]   [Full Text] [Related]  

  • 11. Two-year clinical follow up of coronary drug-eluting stent in patients at high risk for coronary restenosis.
    Azzarelli S; Amico F; Galassi AR; Giacoppo M; Argentino V; Fiscella A
    J Invasive Cardiol; 2008 Feb; 20(2):62-6. PubMed ID: 18252969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents.
    Hoffmann R; Stellbrink E; Schröder J; Grawe A; Vogel G; Blindt R; Kelm M; Radke PW
    Am J Cardiol; 2007 Nov; 100(9):1347-52. PubMed ID: 17950788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there delayed restenosis in patients with coronary artery disease treated with sirolimus-eluting stent?
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Coron Artery Dis; 2007 Jun; 18(4):293-8. PubMed ID: 17496493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease.
    Minutello RM; Bhagan S; Sharma A; Slotwiner AJ; Feldman DN; Cuomo LJ; Wong SC
    J Interv Cardiol; 2007 Dec; 20(6):458-65. PubMed ID: 18042050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial).
    Rodriguez AE; Alemparte MR; Vigo CF; Pereira CF; Llaurado C; Russo M; Virmani R; Ambrose JA
    J Invasive Cardiol; 2003 Oct; 15(10):581-4. PubMed ID: 14519892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
    Grube E; Sonoda S; Ikeno F; Honda Y; Kar S; Chan C; Gerckens U; Lansky AJ; Fitzgerald PJ
    Circulation; 2004 May; 109(18):2168-71. PubMed ID: 15123533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry).
    Waksman R; Buch AN; Torguson R; Xue Z; Smith K; Javaid A; Chu WW; Satler LF; Kent KM; Pichard AD;
    Am J Cardiol; 2007 Jul; 100(1):45-51. PubMed ID: 17599439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.
    Rodriguez A; Rodríguez Alemparte M; Fernández Pereira C; Sampaolesi A; da Rocha Loures Bueno R; Vigo F; Obregón A; Palacios IF;
    Am J Med; 2005 Jul; 118(7):743-51. PubMed ID: 15989908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.